B. Riley Issues Pessimistic Forecast for Lantheus Earnings

Lantheus Holdings, Inc. (NASDAQ:LNTH) – Equities research analysts at B. Riley dropped their Q3 2025 earnings per share (EPS) estimates for shares of Lantheus in a research note issued on Monday, September 15th. B. Riley analyst Y. Zhi now expects that the medical equipment provider will post earnings of $1.02 per share for the quarter, down from their prior estimate of $1.36. B. Riley currently has a “Buy” rating and a $84.00 price target on the stock. The consensus estimate for Lantheus’ current full-year earnings is $6.01 per share. B. Riley also issued estimates for Lantheus’ Q4 2025 earnings at $1.01 EPS and FY2025 earnings at $4.70 EPS.

Lantheus (NASDAQ:LNTH) last posted its earnings results on Wednesday, August 6th. The medical equipment provider reported $1.57 earnings per share for the quarter, missing analysts’ consensus estimates of $1.65 by ($0.08). Lantheus had a net margin of 17.82% and a return on equity of 34.06%. The company had revenue of $378.05 million for the quarter, compared to analysts’ expectations of $389.69 million. During the same period in the previous year, the firm earned $1.80 EPS. The firm’s quarterly revenue was down 4.1% compared to the same quarter last year.

LNTH has been the topic of several other reports. TD Cowen lowered their target price on shares of Lantheus from $95.00 to $80.00 and set a “buy” rating on the stock in a research note on Monday. Mizuho decreased their price target on shares of Lantheus from $120.00 to $70.00 and set an “outperform” rating on the stock in a report on Thursday, August 7th. William Blair reiterated a “market perform” rating on shares of Lantheus in a research report on Wednesday, July 16th. Truist Financial set a $63.00 price objective on Lantheus and gave the company a “hold” rating in a research note on Monday, August 11th. Finally, JMP Securities reduced their target price on Lantheus from $112.00 to $73.00 and set a “market outperform” rating for the company in a research report on Thursday, August 7th. Five analysts have rated the stock with a Buy rating and two have issued a Hold rating to the company’s stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $85.50.

Lantheus Price Performance

LNTH stock opened at $51.56 on Thursday. The firm has a 50 day moving average of $61.53 and a 200-day moving average of $80.20. The firm has a market capitalization of $3.51 billion, a P/E ratio of 13.71 and a beta of 0.15. Lantheus has a 12 month low of $47.25 and a 12 month high of $118.21. The company has a current ratio of 4.29, a quick ratio of 4.07 and a debt-to-equity ratio of 0.49.

Insider Transactions at Lantheus

In related news, insider Farallon Partners L. L. C/Ca sold 3,365,000 shares of the firm’s stock in a transaction dated Wednesday, August 20th. The stock was sold at an average price of $56.15, for a total transaction of $188,944,750.00. Following the transaction, the insider directly owned 3,477,227 shares of the company’s stock, valued at approximately $195,246,296.05. This trade represents a 49.18% decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through this link. Also, insider Rajiv A. Patel sold 3,365,000 shares of the business’s stock in a transaction that occurred on Wednesday, August 20th. The stock was sold at an average price of $56.15, for a total value of $188,944,750.00. Following the completion of the sale, the insider owned 3,477,227 shares of the company’s stock, valued at $195,246,296.05. The trade was a 49.18% decrease in their position. The disclosure for this sale can be found here. Insiders have sold 6,812,000 shares of company stock worth $382,427,380 in the last 90 days. Company insiders own 1.50% of the company’s stock.

Institutional Inflows and Outflows

Large investors have recently made changes to their positions in the business. State of Michigan Retirement System boosted its stake in shares of Lantheus by 0.6% in the 1st quarter. State of Michigan Retirement System now owns 16,600 shares of the medical equipment provider’s stock valued at $1,620,000 after purchasing an additional 100 shares in the last quarter. Signaturefd LLC lifted its stake in Lantheus by 36.5% in the first quarter. Signaturefd LLC now owns 434 shares of the medical equipment provider’s stock worth $42,000 after purchasing an additional 116 shares during the last quarter. Intrust Bank NA boosted its position in Lantheus by 2.9% during the first quarter. Intrust Bank NA now owns 4,417 shares of the medical equipment provider’s stock valued at $431,000 after buying an additional 125 shares during the period. Focus Financial Network Inc. grew its stake in shares of Lantheus by 4.0% during the second quarter. Focus Financial Network Inc. now owns 3,576 shares of the medical equipment provider’s stock valued at $293,000 after buying an additional 136 shares during the last quarter. Finally, Nisa Investment Advisors LLC grew its stake in shares of Lantheus by 2.1% during the first quarter. Nisa Investment Advisors LLC now owns 6,691 shares of the medical equipment provider’s stock valued at $653,000 after buying an additional 139 shares during the last quarter. 99.06% of the stock is owned by hedge funds and other institutional investors.

Lantheus Company Profile

Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer.